Overview


According to FutureWise analysis, the market for Adenovirus Diagnostic Testing is expected to grow at a CAGR of 7.10% over the forecast period of 2023-2031.

Adenoviruses are a family of DNA viruses responsible for inducing febrile illnesses in youngsters. They are associated with upper respiratory tract syndromes such as pharyngitis or coryza but can also cause pneumonia. Less commonly, adenoviruses cause gastrointestinal, genitourinary, ophthalmologic, neurologic, and disseminated disease. Most adenoviral diseases are transient, although fatal infections can occur in immunocompromised hosts and occasionally in healthy youngsters and adults. Since adenoviruses are associated with various clinical syndromes and nonspecific manifestations, diagnosis based on clinical criteria alone is challenging. The diagnosis of adenovirus disease should be confirmed in outbreaks of infection and individual patients with serious disease manifestations. Confirmation of adenovirus infection is essential to decide on antiviral agents, exclude other treatable conditions, establish a prognosis, and initiate infection control measures when appropriate.

Earlier diagnostic approaches to Adenovirus detection relied mainly on serological tests and cell culture. In immunosuppressed patients, however, the use of serological tests is limited due to the impaired immune response, and evaluation of positive cultures is a relatively slow method. The recent introduction of PCR-based assays has opened new ways to rapid, specific, and susceptible AdV detection. However, many of these diagnostic approaches need to effectively cover all AdV types or use lower-stringency conditions to permit the detection of genetically highly diverse adenoviruses.

FutureWise Market Research has published a report that provides an insightful analysis adenovirus diagnostic testing market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.

According to the analysis conducted by FutureWise research analysts, adenovirus diagnostic testing market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Affymetrix Inc
  • Becton Dickinson and Company
  • Roche
  • Novartis AG
  • Qiagen N.V.
  • DiaSorin Inc
  • Abbott Laboratories
  • BioMerieux Inc

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in Adenovirus Diagnostic Testing Market:

  • In July 2021, QIAGEN N.V. announced that its NeuMoDx™ HAdV Quant Assay secured identification and quantification CE-IVD certification for human adenovirus (HAdV) DNA testing for the European Union and other regions that accept this certification marking.

The rising incidence of potential diagnostic and prognostic biomarkers for adenovirus respiratory infections is expected to drive market growth during the forecast period. These biomarkers allow more accurate and early detection of adenovirus infections, helping healthcare providers to diagnose and initiate proper treatment. Moreover, by identifying prognostic biomarkers that indicate the severity and potential complications of the disease, healthcare professionals could better tailor patient care, leading to improved outcomes. This increasing focus on biomarker-based diagnostics enhances patient care and presents a promising opportunity for innovation and growth within the adenovirus diagnostics testing market. Additionally, adenovirus vectors serve as a significant driver in gene therapy and vaccine development. These vectors are widely used in cancer gene therapy due to their efficiency in delivering therapeutic genes to target cells, offering new hope in the combat against various forms of cancer. Additionally, their adaptability rises to vaccine development, where they are used to express foreign antigens, paving the way for the invention of effective vaccines against infectious diseases, which is further expected to fuel the demand for adenovirus diagnostics testing market. Furthermore, inadequate healthcare infrastructure and limited access to diagnostic facilities in several developing regions are expected to hamper the market growth. In these areas, a shortage of well-equipped healthcare structures, skilled professionals, and diagnostic resources limits the convenient and accurate diagnosis of adenovirus conditions. This healthcare infrastructure deficit poses a significant restraint, impeding market expansion over the forecast period. Moreover, the emergence of novel viral threats presents a significant obstacle in the adenovirus diagnostics testing market. When new viral outbreaks arise, they often demand immediate attention, resources, and research efforts from healthcare institutions and governments. In such cases, the shifts towards containing the newly identified pathogens, allotting funding and developing diagnostic tools and vaccines specific to the emerging threat. This diversion of resources and attention might temporarily surpass the significance of adenovirus diagnostics testing, potentially hindering market growth.

By Diagnostic Method

  • Viral Culture
  • Polymerase Chain Reaction Assays and AntigenBased assays
  • Monoclonal Antibodies
  • Liposomes and Flow Cytometry
  • Chromatography
  • Gel Microdroplets

By Assay Type

  • PCR Assay kits
  • Antigen Detection Kits
  • Others

By End-User

  • Hospitals
  • Diagnostic Laboratories
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Owing to increased public health concerns regarding infectious diseases, such as pneumonia, associated with adenovirus infection, government initiatives, several private diagnostics laboratories and hospitals in the U.S. and Canada provide a range of portfolio tests to detect the existence of adenovirus are expected to drive the growth of the market over the projection period. Also, rising demand for advanced molecular diagnostics tests, technological advancements in molecular diagnostics such as polymerase chain reaction and nucleic acid amplification tests (NAATs), and development in the incidence of adenovirus are projected to boost the growth of the adenovirus diagnostics testing market.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Adenovirus Diagnostic Testing Market By Diagnostic Method, By Type, By End User and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customisation offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

 

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Adenovirus Diagnostic Testing Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Adenovirus Diagnostic Testing Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Adenovirus Diagnostic Testing Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Adenovirus Diagnostic Testing Market, By Diagnostic Method Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Viral Culture
        2. Polymerase Chain Reaction Assays and AntigenBased assays
        3. Monoclonal Antibodies
        4. Liposomes and Flow Cytometry
        5. Chromatography
        6. Gel Microdroplets

  • 8.   Adenovirus Diagnostic Testing Market, By Assay Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. PCR Assay kits
        2. Antigen Detection Kits
        3. Others

  • 9.   Adenovirus Diagnostic Testing Market, By End-User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Diagnostic Laboratories
        3. Others

  • 10.   North America Adenovirus Diagnostic Testing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Adenovirus Diagnostic Testing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Adenovirus Diagnostic Testing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Adenovirus Diagnostic Testing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Adenovirus Diagnostic Testing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Affymetrix Inc
           1.1. Company Overview
           1.2. Product Portfolio
           1.3. SWOT Analysis
           1.4. Financial Overview
           1.5. Strategic Overview
        2. Becton Dickinson and Company
           2.1. Company Overview
           2.2. Product Portfolio
           2.3. SWOT Analysis
           2.4. Financial Overview
           2.5. Strategic Overview
        3. Roche
           3.1. Company Overview
           3.2. Product Portfolio
           3.3. SWOT Analysis
           3.4. Financial Overview
           3.5. Strategic Overview
        4. Novartis AG
           4.1. Company Overview
           4.2. Product Portfolio
           4.3. SWOT Analysis
           4.4. Financial Overview
           4.5. Strategic Overview
        5. Qiagen N.V.
           5.1. Company Overview
           5.2. Product Portfolio
           5.3. SWOT Analysis
           5.4. Financial Overview
           5.5. Strategic Overview
        6. DiaSorin Inc
           6.1. Company Overview
           6.2. Product Portfolio
           6.3. SWOT Analysis
           6.4. Financial Overview
           6.5. Strategic Overview
        7. Abbott Laboratories
           7.1. Company Overview
           7.2. Product Portfolio
           7.3. SWOT Analysis
           7.4. Financial Overview
           7.5. Strategic Overview
        8. BioMerieux Inc
           8.1. Company Overview
           8.2. Product Portfolio
           8.3. SWOT Analysis
           8.4. Financial Overview
           8.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients